Skip to content
All resources

Testing, quality and handling

Peptide Sequencing by Tandem Mass Spectrometry: b Ions, y Ions and What They Prove

NB

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. What does an intact mass actually establish?
  2. How does fragmentation spell out a sequence?
  3. CID, HCD and ETD: what each one breaks
  4. Why can leucine and isoleucine not be told apart?
  5. What else can a spectrum get wrong?
  6. What should a certificate show?
  7. Frequently asked questions

Tandem mass spectrometry reads a peptide's sequence by isolating the intact ion, breaking it into fragments, and measuring the fragment masses. Consecutive fragments differ by the mass of one residue, so the series spells out the order of the residues. An intact mass alone cannot do this: it constrains composition only, and any rearrangement of the same residues gives the same number. MS/MS is how a certificate moves from "the right molecular weight is present" to "the right sequence is present".

A peptide chain breaking into a ladder of fragments of decreasing length
Illustration: tandem mass spectrometry reads a sequence from its fragments.

What does an intact mass actually establish?

Less than it appears to. A molecular weight is a sum. Every permutation of a sequence has the same sum, as does any swap of residues whose masses happen to cancel — and several do. Leucine and isoleucine are exactly isobaric. Glutamine and lysine differ by about 0.036 Da, which an ordinary instrument will not separate. Three glycines weigh the same as one asparagine plus one alanine.

So an intact mass is a strong constraint and a weak proof. It rules out most wrong molecules and confirms none. For a synthetic peptide, the impurities most likely to be present are the ones synthesis creates — deletions, truncations, incompletely deprotected chains — and some of those are mass-distinguishable while others are not. The synthesis side of that is set out in solid-phase peptide synthesis; the detection side is in HPLC and LC-MS testing.

How does fragmentation spell out a sequence?

Fragments are named by a scheme Roepstorff and Fohlman proposed in a single page in 1984, which the field adopted and has not replaced (PMID 6525415). A peptide backbone can break at three bonds, and each break gives two fragments depending on which side keeps the charge. The N-terminal fragments are a, b and c; the C-terminal ones are x, y and z. A subscript counts residues: b3 holds the first three, y4 the last four.

Ion pairBond brokenUsually produced by
b and ythe amide bondcollision-induced dissociation, higher-energy collisional dissociation
c and zthe N–Cα bondelectron capture and electron transfer dissociation
a and xthe Cα–C bondhigher collision energies, as a by-product

The reading is subtraction. Line up the b ions in order and the gap between b2 and b3 is the mass of residue three. Do the same with the y series from the other end. Two independent readings of the same sequence, running in opposite directions, is what makes a good spectrum convincing. Steen and Mann's review remains the clearest account of how an analyst actually walks a spectrum (PMID 15340378).

Hunt and colleagues demonstrated the whole approach as a practical protein-sequencing method in 1986, on peptides from apolipoprotein B analysed without further purification after fractionation (PMID 3462691). Everything since is refinement of the activation step.

CID, HCD and ETD: what each one breaks

Collision-induced dissociation (CID) accelerates the isolated ion into inert gas. The energy redistributes over the molecule and the weakest bonds give way, which for a protonated peptide is usually the amide backbone, yielding b and y ions. Where the proton sits governs which amide breaks. Wysocki and colleagues set out the mobile-proton framework that explains this, including why cleavage is enhanced next to aspartate when the charge is sequestered elsewhere, and why protonated histidine drives cleavage by a different route (PMID 11180630).

Higher-energy collisional dissociation (HCD) performs the collision in a dedicated cell and records the products at high accuracy across the full mass range. Olsen and colleagues introduced it on an orbitrap instrument and showed it generates immonium ions that pinpoint modifications with high confidence (PMID 17721543). In practice HCD gives cleaner low-mass information than ion-trap CID, which loses fragments below a cut-off.

Electron transfer dissociation (ETD) is a different chemistry. Syka and colleagues showed that singly charged anthracene anions transfer an electron to a multiply protonated peptide, inducing backbone cleavage along pathways analogous to electron capture dissociation and yielding c and z ions (PMID 15210983). Zubarev and colleagues had established the parent technique, electron capture dissociation, for multiply charged protein cations (PMID 10695143).

The practical difference is what survives. Collisional methods tend to shed labile groups before the backbone breaks. Electron-driven methods cleave the backbone while leaving those groups attached, which is why ETD is the method of choice for modified peptides and for longer, more highly charged ions. The two are complementary rather than ranked, and many instruments now run both on the same precursor.

Why can leucine and isoleucine not be told apart?

Because they are structural isomers: the same atoms, arranged differently, and therefore the same mass to any mass analyser at any resolution. A b/y series will read "113 Da" at that position and stop there. The same problem, in milder form, affects glutamine and lysine, separable only at high resolving power.

Two routes get round it, and both work by breaking the side chain rather than the backbone.

Armirotti and colleagues exploited a gas-phase fragmentation of isoleucine that yields a diagnostic ion at 69 Da in consecutive stages of fragmentation, assigning residues correctly in most peptides of a myoglobin digest on a low-resolution ion trap (PMID 17010643). Lebedev and colleagues used a different route on a high-resolution instrument: isolate the odd-electron z ions produced by electron transfer, fragment them again, and read the resulting w ions, which differ between the two isomers. Applied to six natural peptides of 15 to 37 residues, the method resolved all 22 Leu/Ile positions (PMID 24940639).

Neither is routine on a commercial certificate. What that means in practice is that a certificate reporting a sequence confirmation has usually confirmed everything except which of these isomers sits at each such position — and for a catalogue peptide, the intended sequence supplies that by assumption, not by measurement.

What else can a spectrum get wrong?

The quiet failure mode is sequence scrambling. Bleiholder and colleagues studied the b and a fragments of five cyclic permutations of the same pentapeptide amide and found that the b5 ions of all of them gave nearly identical dissociation patterns, matching the spectrum of the corresponding cyclic peptide. Their interpretation, supported by computation, is that the linear b ion cyclises and reopens at a different amide before fragmenting further, which can in principle destroy the sequence information entirely — as it did for one of their peptides (PMID 19055406).

This is not a common catastrophe, but it is the reason a sequence read from a single ion series with gaps in it is weaker evidence than two complementary series that agree.

Three other limits are worth naming:

  • Coverage. A spectrum rarely yields every fragment. Gaps mean a stretch of sequence is inferred rather than read, and an impurity differing inside that stretch would not be seen.
  • Stereochemistry. Fragmentation does not distinguish a D-residue from an L-residue; the masses are identical. That question needs the chiral chemistry described in D-amino acids in peptides.
  • Which molecule was fragmented. A sequence confirmed on an isolated precursor says nothing about the proportion of the vial that precursor represents. Quantity is a chromatographic measurement, and the share of the mass that is peptide at all is a third question again, covered in net content versus purity.

What should a certificate show?

For identity, more than one number. The theoretical and observed monoisotopic or average masses, the charge states seen, and the ionisation mode are the minimum. A report claiming sequence confirmation should show the annotated MS/MS spectrum, name the activation method, and state the sequence coverage — which fragments were assigned and which were not.

Most research-chemical certificates do none of this. They report an HPLC purity figure and, at best, an intact mass. That is enough to establish that something of about the right weight is the main component, and not enough to establish the order of its residues. The wider question of what any certificate does and does not cover is in what a certificate of analysis establishes, and the composition-level check that complements this one is amino acid analysis. For peptides held together by cysteine pairs, the connectivity is yet another separate determination — see disulfide bonds in peptides. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

What is the difference between MS and MS/MS for a peptide? A single-stage measurement weighs the intact molecule and gives one number, which constrains composition. Tandem mass spectrometry isolates that molecule, breaks it, and weighs the pieces. The differences between consecutive pieces are residue masses, so the second measurement reads an order that the first cannot see at all.

Why are b and y ions the ones usually discussed? Because collision-based fragmentation, still the most common activation method, breaks the amide bond preferentially and produces them. Electron-driven methods such as ETD break a different backbone bond and produce c and z ions instead. Both read the same sequence; they simply cut it in different places and tolerate different modifications.

Can MS/MS detect a single wrong residue? Usually, provided fragments bracket the position. A substitution changes the mass of every fragment containing that residue, shifting part of both series. It will be missed if the substituted residue is isobaric with the intended one, if the swap is a D-form of the same residue, or if that stretch of sequence produced no fragments.

Does a reported molecular weight on a certificate confirm the sequence? No. It confirms that a species of that mass was detected. Permutations, several isobaric substitutions and some rearrangements all share a mass with the intended peptide. Treating an intact mass as sequence confirmation is the single commonest overreading of a peptide certificate.

Is high resolution enough to separate leucine from isoleucine? No. They are isomers with identical elemental composition, so no mass analyser separates them at any resolving power. Distinguishing them requires side-chain fragmentation — a diagnostic secondary fragment in multi-stage experiments, or w ions generated from electron-transfer products — and neither is standard on commercial reports.

Selected Research References

  1. Roepstorff P, Fohlman J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomedical Mass Spectrometry. 1984;11(11):601. pubmed.ncbi.nlm.nih.gov/6525415
  2. Hunt DF, Yates JR 3rd, Shabanowitz J, et al. Protein sequencing by tandem mass spectrometry. Proceedings of the National Academy of Sciences. 1986;83(17):6233-6237. pubmed.ncbi.nlm.nih.gov/3462691
  3. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nature Reviews Molecular Cell Biology. 2004;5(9):699-711. pubmed.ncbi.nlm.nih.gov/15340378
  4. Syka JE, Coon JJ, Schroeder MJ, et al. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proceedings of the National Academy of Sciences. 2004;101(26):9528-9533. pubmed.ncbi.nlm.nih.gov/15210983
  5. Zubarev RA, Horn DM, Fridriksson EK, et al. Electron capture dissociation for structural characterization of multiply charged protein cations. Analytical Chemistry. 2000;72(3):563-573. pubmed.ncbi.nlm.nih.gov/10695143
  6. Olsen JV, Macek B, Lange O, et al. Higher-energy C-trap dissociation for peptide modification analysis. Nature Methods. 2007;4(9):709-712. pubmed.ncbi.nlm.nih.gov/17721543
  7. Wysocki VH, Tsaprailis G, Smith LL, et al. Mobile and localized protons: a framework for understanding peptide dissociation. Journal of Mass Spectrometry. 2000;35(12):1399-1406. pubmed.ncbi.nlm.nih.gov/11180630
  8. Armirotti A, Millo E, Damonte G. How to discriminate between leucine and isoleucine by low energy ESI-TRAP MSn. Journal of the American Society for Mass Spectrometry. 2007;18(1):57-63. pubmed.ncbi.nlm.nih.gov/17010643
  9. Lebedev AT, Damoc E, Makarov AA, et al. Discrimination of leucine and isoleucine in peptides sequencing with Orbitrap Fusion mass spectrometer. Analytical Chemistry. 2014;86(14):7017-7022. pubmed.ncbi.nlm.nih.gov/24940639
  10. Bleiholder C, Osburn S, Williams TD, et al. Sequence-scrambling fragmentation pathways of protonated peptides. Journal of the American Chemical Society. 2008;130(52):17774-17789. pubmed.ncbi.nlm.nih.gov/19055406

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.